Biohaven [BHVN] vs Regeneron [REGN] Detailed Stock Comparison

Biohaven Ltd.

NYSE
Loading...

Regeneron Pharmaceuticals, Inc.

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 21 vital metrics comparison: Biohaven Ltd. wins in 0 metrics, Regeneron Pharmaceuticals, Inc. wins in 14 metrics, with 0 ties. Regeneron Pharmaceuticals, Inc. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Biohaven Ltd. Regeneron Pharmaceuticals, Inc. Better
P/E Ratio (TTM) N/A 18.00 N/A
Price-to-Book Ratio 26.84 2.45 Regeneron Pharmaceuticals, Inc.
Debt-to-Equity Ratio 546.58 9.51 Regeneron Pharmaceuticals, Inc.
PEG Ratio -5.26 -4.80 Regeneron Pharmaceuticals, Inc.
EV/EBITDA -2.22 16.72 Regeneron Pharmaceuticals, Inc.
Profit Margin (TTM) 0.00% 31.41% Regeneron Pharmaceuticals, Inc.
Operating Margin (TTM) 0.00% 23.13% Regeneron Pharmaceuticals, Inc.
EBITDA Margin (TTM) N/A 23.13% N/A
Return on Equity -310.75% 14.86% Regeneron Pharmaceuticals, Inc.
Return on Assets (TTM) -83.02% 5.91% Regeneron Pharmaceuticals, Inc.
Free Cash Flow (TTM) $-610.15M $3.77B Regeneron Pharmaceuticals, Inc.
Dividend Yield N/A 0.59% N/A
1-Year Return -27.04% 15.66% Regeneron Pharmaceuticals, Inc.
Price-to-Sales Ratio (TTM) N/A 5.50 N/A
Enterprise Value $1.55B $70.98B Regeneron Pharmaceuticals, Inc.
EV/Revenue Ratio N/A 4.95 N/A
Gross Profit Margin (TTM) N/A 84.95% N/A
Revenue per Share (TTM) N/A $137 N/A
Earnings per Share (Diluted) $-6.86 $41.48 Regeneron Pharmaceuticals, Inc.
Beta (Stock Volatility) 3.62 0.40 Regeneron Pharmaceuticals, Inc.
Short % of Float 20.25% 2.55% Regeneron Pharmaceuticals, Inc.

Biohaven Ltd. vs Regeneron Pharmaceuticals, Inc. Stock Performance Analysis

Loading Price Chart...

BHVN
REGN

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Biohaven Ltd.7.62%9.17%38.58%25.93%7.62%11.99%
Regeneron Pharmaceuticals, Inc.0.46%0.60%-11.93%-18.75%-18.29%-20.78%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Biohaven Ltd.-27.04%-52.30%54.52%-37.02%-37.02%-37.02%
Regeneron Pharmaceuticals, Inc.15.66%-21.83%13.80%72.82%1,033.17%4,804.97%

Performance & Financial Health Analysis: Biohaven Ltd. vs Regeneron Pharmaceuticals, Inc.

MetricBHVNREGN
Market Information
Market Cap i$1.49B$80.98B
Market Cap CategorySmall capLarge cap
10 Day Avg. Volume i1,841,635642,495
90 Day Avg. Volume i2,141,992617,765
Last Close$12.14$614.98
52 Week Range$7.48 - $18.57$503.25 - $821.11
% from 52W High-34.61%-25.10%
All-Time High$67.86 (Jun 03, 2019)$1,211.20 (Aug 26, 2024)
% from All-Time High-82.11%-49.23%
Growth Metrics
Quarterly Revenue GrowthN/A0.03%
Quarterly Earnings GrowthN/A-0.08%
Financial Health
Profit Margin (TTM) i0.00%0.31%
Operating Margin (TTM) i0.00%0.23%
Return on Equity (TTM) i-3.11%0.15%
Debt to Equity (MRQ) i546.589.51
Cash & Liquidity
Book Value per Share (MRQ)$0.39$304.65
Cash per Share (MRQ)$2.12$83.86
Operating Cash Flow (TTM) i$-609,438,016$4.98B
Levered Free Cash Flow (TTM) i$-358,118,432$3.26B
Dividends
Last 12-Month Dividend Yield iN/A0.59%
Last 12-Month Dividend iN/A$4.46

Valuation & Enterprise Metrics Analysis: Biohaven Ltd. vs Regeneron Pharmaceuticals, Inc.

MetricBHVN (Apr 26, 2026)REGN (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) iN/A18.00
Forward P/E i-5.2614.21
PEG Ratio i-5.26-4.80
Price to Sales (TTM) iN/A5.50
Price to Book (MRQ) i26.842.45
Market Capitalization
Market Capitalization i$1.49B$80.98B
Enterprise Value i$1.55B$70.98B
Enterprise Value Metrics
Enterprise to Revenue iN/A4.95
Enterprise to EBITDA i-2.2216.72
Risk & Other Metrics
Beta i3.620.40
Book Value per Share (MRQ) i$0.39$304.65

Financial Statements Comparison: Biohaven Ltd. vs Regeneron Pharmaceuticals, Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricBHVN (2025)REGN (2025)
Revenue/Sales i014.34B
Cost of Goods Sold iN/A2.10B
COGS % of Revenue i-14.6%
Gross Profit iN/A12.24B
Gross Margin i-85.4%
Research & Development i635.07M5.85B
Operating Income (EBIT) i-745.38M3.70B
Operating Margin i-25.8%
EBITDA i-735.46M5.00B
EBITDA Margin i-34.8%
Pre-Tax Income i-737.38M5.23B
Pre-Tax Income % of Revenue i-36.5%
Income Tax i1.44M725.80M
Income Tax % of Revenue i-5.1%
Net Income (Profit) i-738.82M4.50B
Profit Margin i-31.4%

Balance Sheet & Liquidity Metrics

MetricBHVN (2025)REGN (2025)
Cash & Equivalents i229.96M3.12B
Total Current Assets i368.33M18.02B
Total Current Assets % of Revenue i-125.7%
Total Current Liabilities i115.93M4.37B
Total Current Liabilities % of Revenue i-30.5%
Long-Term Debt i278.86M2.71B
Long-Term Debt % of Revenue i-18.9%
Total Shareholders Equity i52.07M31.26B
Retained Earnings i-2.08B35.80B
Retained Earnings % of Revenue i-249.6%
Property, Plant & Equipment i45.06M1.54B

Cash Flow Statement Comparison

MetricBHVN (2025)REGN (2025)
Operating Cash Flow i-617.91M6.30B
Operating Cash Flow % of Revenue i-43.9%
Capital Expenditures i-715,0000
Free Cash Flow i-610.15M3.77B
FCF Margin i-26.3%
Debt Repayment iN/AN/A
Common Stock Repurchase iN/A-3.97B

Short Interest & Institutional Ownership Analysis

MetricBHVNREGN
Shares Short i23.77M2.55M
Short Ratio i9.214.46
Short % of Float i20.25%2.55%
Shares Outstanding i132.78M105.72M
Float Shares i123.86M98.55M
% Held by Insiders i11.09%1.98%
% Held by Institutions i91.64%91.08%
% Held by Public i-2.73%6.94%

Dividend Analysis & Yield Comparison: Biohaven Ltd. vs Regeneron Pharmaceuticals, Inc.

MetricBHVNREGN
Last 12-Month Dividend iN/A$4.46
Last 12-Month Dividend Yield iN/A0.59%
3-Year Avg Annual Dividend iN/A$1.49
3-Year Avg Dividend Yield iN/A0.13%
3-Year Total Dividends iN/A$4.46
Ex-Dividend DateN/AFeb 20, 2026